Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution?

Molecules

James M. Smoliga¹  Otis Blanchard² 

[1] Department of Physical Therapy, School of Health Sciences, High Point University, High Point, NC 27262, USA;Wilmore Labs LLC, San Antonio, TX 78250, USA

关键词: pharmacokinetics;    pharmacodynamics;    phytochemical;    nutraceutical;    red wine;    sirtuins;    SIRT1;    stilbene;   

DOI  :  10.3390/molecules191117154

来源: mdpi

【 摘 要 】

Resveratrol has emerged as a leading candidate for improving healthspan through potentially slowing the aging process and preventing chronic diseases. The poor bioavailability of resveratrol in humans has been a major concern for translating basic science findings into clinical utility. Although a number of positive findings have emerged from human clinical trials, there remain many conflicting results, which may partially be attributed to the dosing protocols used. A number of theoretical solutions have been developed to improve the bioavailability of resveratrol, including consumption with various foods, micronized powders, combining it with additional phytochemicals, controlled release devices, and nanotechnological formulations. While laboratory models indicate these approaches all have potential to improve bioavailability of resveratrol and optimize its clinical utility, there is surprisingly very little data regarding the bioavailability of resveratrol in humans. If bioavailability is indeed a limitation in the clinical utility of resveratrol, there is a need to further explore methods to optimize bioavailability in humans. This review summarizes the current bioavailability data, focusing on data from humans, and provides suggested directions for future research in this realm.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.